Molecular Genetics of Schizophrenia - nonGAIN Sample (MGS_nonGAIN)

This study is part of the Molecular Genetics of Schizophrenia (MGS) genome wide association study (GWAS) of 3,972 cases (2,686 EA and 1,286 AA) and 3,629 controls (2,656 EA and 973 AA) (analyzed sample remaining after quality control exclusions), comprised of European ancestry (EA) and African American (AA) samples. We genotyped about half of the EA sample and almost all of the AA sample under the auspices of the Genetic Association Information Network (GAIN) with the Affymetrix 6.0 platform at the Broad Institute. The remainder of the included sample was also genotyped with the Affymetrix 6.0 platform at the Broad Institute, and we refer to this component as the nonGAIN sample. Cases met criteria for schizophrenia (SCZ) or schizoaffective disorder (SA) per the Diagnostic and Statistical Manual of Mental Disorders version IV (DSM-IV) for all three collections (SGI, MGS1, and MGS2) comprising these cases. However, for the older SGI collection, codes for the secondary diagnoses refer to the older DSM-III-R version. Controls were screened briefly and excluded if they endorsed a history of these illnesses.

• Study Design:
  • Case-Control
• Study Type:
  • Case-Control
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 3029
• Subject Sample Telemetry Report (SSTR)

• PubMed

Please refer to the following documents for detailed information: "Cases_Protocol.pdf" and "Controls_Protocol.pdf". Briefly, all subjects had to give informed consent, be at least 18 years old, and be able to communicate in English. Included cases had a consensus best estimate final diagnosis of DSM-IV SCZ or SA. Cases were excluded if they had worse than mild mental retardation, or if their psychotic illness was judged to be secondary to substance use or a neurological disorder. Some case parents were included to make trios that were only used for quality control purposes (e.g., Mendelian checks of SNPs). Controls were excluded if they did not deny all of the following psychosis screening questions: treatment for or diagnosis of schizophrenia or schizoaffective disorder; treatment for or diagnosis of bipolar disorder or manic-depression; treatment for or diagnosis of psychotic symptoms such as auditory hallucinations or persecutory delusions.

Samples were collected under the following grants: NIMH Schizophrenia Genetics Initiative U01s: MH46276, MH46289, and MH46318; and Molecular Genetics of Schizophrenia Part 1 (MGS1) and Part 2 (MGS2) R01s: MH67257, MH59588, MH59571, MH59565, MH59587, MH60870, MH60879, MH59566, MH59586, and MH61675. Genotyping and analyses were funded under the MGS U01s: MH79469 and MH79470.

• Primary Phenotype: Schizophrenia
• Psychotic Disorders

• Lead Principal Investigator and MGS Site Principal Investigator
  • Pablo V. Gejman, MD. NorthShore University HealthSystem, Evanston, IL, USA.
• Statistical Task Force Chair, MGS Site Principal Investigator, Clinical Database
  • Douglas F. Levinson, MD. Stanford University School of Medicine, Palo Alto, CA, USA.
• MGS Site Principal Investigators
  • Bryan J. Mowry, MD. Queensland Centre for Mental Health Research, and University of Queensland, Brisbane, Queensland, Australia.
  • Nancy G. Buccola, APRN., CNS-BC. Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Farooq Amin, MD. Atlanta Veterans Affairs Medical Center, and Emory University School of Medicine, Atlanta, GA, USA.
  • Donald W. Black, MD. University of Iowa Carver College of Medicine, Iowa City, IA, USA.
  • Jeremy M. Silverman, PhD. Mount Sinai School of Medicine, New York, NY, USA.
  • William F. Byerley, MD. University of California at San Francisco, San Francisco, CA, USA.
  • C. Robert Cloninger, MD. Washington University, St. Louis, MO, USA.
  • Robert Freedman, MD. University of Colorado Denver, Aurora, CO, USA.
• Other Investigators, Laboratory
  • Jubao Duan, PhD. NorthShore University HealthSystem, Evanston, IL, USA.
• Statisticians
  • Frank Dudbridge, PhD. Medical Research Council (MRC) Biostatistics Unit, Cambridge, England, United Kingdom.
  • Peter A. Holmans, PhD. Cardiff University, Cardiff, Wales, United Kingdom.
  • Jianxin Shi, PhD. Stanford University School of Medicine, Palo Alto, CA, USA.
  • Alice Whittemore, PhD. Stanford University School of Medicine, Palo Alto, CA, USA.
  • Maria Martinez, PhD. Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
• Other Investigators, Statistical Consultant
  • Itsik Pe'er, PhD. Columbia University, New York, NY, USA.
• Other Investigators, Phenotypic
  • Kenneth S. Kendler, MD. Virginia Commonwealth University, Richmond, VA, USA.
  • Ayman H. Fanous, MD. Washington Veterans Affairs Medical Center, Washington, DC, USA.
• Other Investigators, Database
  • John P. Rice, PhD. Washington University, St. Louis, MO, USA.
• Other Investigators, Database, Quality Assurance
  • Alan R. Sanders, MD. NorthShore University HealthSystem, Evanston, IL, USA.
• Institutions
  • NorthShore University HealthSystem, Evanston, IL, USA.
  • Northwestern University, Evanston, IL, USA.
  • Stanford University School of Medicine, Palo Alto, CA, USA.
  • Queensland Centre for Mental Health Research, Brisbane, Queensland, Australia.
  • University of Queensland, Brisbane, Queensland, Australia.
  • Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA.
  • Emory University School of Medicine, Atlanta, GA, USA.
  • University of Iowa Carver College of Medicine, Iowa City, IA, USA.
  • Mount Sinai School of Medicine, New York, NY, USA.
  • University of California at San Francisco, San Francisco, CA, USA.
  • Washington University, St. Louis, MO, USA.
  • University of Colorado Denver, Aurora, CO, USA.
  • Medical Research Council (MRC) Biostatistics Unit, Cambridge, England, United Kingdom.
  • Cardiff University, Cardiff, Wales, United Kingdom.
  • Columbia University, New York, NY, USA.
  • Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
  • Virginia Commonwealth University, Richmond, VA, USA.
  • Washington Veterans Affairs Medical Center, Washington, DC, USA.
• Funding Source - SGI Sample Collections
  • U01 MH46276. National Institutes of Health, Bethesda, MD, USA.
  • U01 MH46289. National Institutes of Health, Bethesda, MD, USA.
  • U01 MH46318. National Institutes of Health, Bethesda, MD, USA.
• Funding Source - MGS1 and MGS2 Sample Collections
  • R01 MH67257. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH59588. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH59571. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH59565. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH59587. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH60870. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH60879. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH59566. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH59586. National Institutes of Health, Bethesda, MD, USA.
  • R01 MH61675. National Institutes of Health, Bethesda, MD, USA.
• Funding Source - Genotyping and Analyses
  • U01 MH79469. National Institutes of Health, Bethesda, MD, USA.
  • U01 MH79470. National Institutes of Health, Bethesda, MD, USA.